Ulipristal Acetate in Adenomyosis.

IF 1.4 Q3 OBSTETRICS & GYNECOLOGY

Gynecology and Minimally Invasive Therapy-GMIT Pub Date : 2022-10-01 DOI:10.4103/gmit.gmit_95_21

Manuel Gonçalves-Henriques, António de Pinho, Marília Freixo, Maria Liz-Coelho, Fabiana Castro, Nathan Ceschin, Pedro Brandão

{"title":"Ulipristal Acetate in Adenomyosis.","authors":"Manuel Gonçalves-Henriques, António de Pinho, Marília Freixo, Maria Liz-Coelho, Fabiana Castro, Nathan Ceschin, Pedro Brandão","doi":"10.4103/gmit.gmit_95_21","DOIUrl":null,"url":null,"abstract":"<p><p>Adenomyosis is defined as the invasion of the basal endometrium (stroma and glands) into the underlying myometrium. It may lead to abnormal uterine bleeding (AUB), pelvic pain, and infertility. The definitive treatment is hysterectomy. Some conservative measures have been used in patients willing to procreate. Ulipristal acetate is a selective progesterone receptor modulator used to treat AUB caused by leiomyomas. This is a systematic review on the use of ulipristal to treat adenomyosis. Eight eligible articles were retrieved from PubMed, SCOPUS, and Cochrane Library. Only one randomized clinical trial was published until date concerning this matter. It seems that ulipristal acetate induces partial or complete remission of AUB caused by adenomyosis, but the evidence concerning its effect on pelvic pain and the radiologic findings of the disease is conflicting. Nevertheless, given the paucity of data, it is still preliminary to draw any conclusion about the subject.</p>","PeriodicalId":45272,"journal":{"name":"Gynecology and Minimally Invasive Therapy-GMIT","volume":"11 4","pages":"198-202"},"PeriodicalIF":1.4000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/8b/GMIT-11-198.PMC9844051.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecology and Minimally Invasive Therapy-GMIT","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/gmit.gmit_95_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Adenomyosis is defined as the invasion of the basal endometrium (stroma and glands) into the underlying myometrium. It may lead to abnormal uterine bleeding (AUB), pelvic pain, and infertility. The definitive treatment is hysterectomy. Some conservative measures have been used in patients willing to procreate. Ulipristal acetate is a selective progesterone receptor modulator used to treat AUB caused by leiomyomas. This is a systematic review on the use of ulipristal to treat adenomyosis. Eight eligible articles were retrieved from PubMed, SCOPUS, and Cochrane Library. Only one randomized clinical trial was published until date concerning this matter. It seems that ulipristal acetate induces partial or complete remission of AUB caused by adenomyosis, but the evidence concerning its effect on pelvic pain and the radiologic findings of the disease is conflicting. Nevertheless, given the paucity of data, it is still preliminary to draw any conclusion about the subject.

Abstract Image

查看原文本刊更多论文

醋酸Ulipristal治疗腺肌炎。

子宫腺肌病的定义是基底子宫内膜(间质和腺体)浸润到下层子宫肌层。它可能导致异常子宫出血(AUB)，盆腔疼痛和不孕。最终的治疗是子宫切除术。一些保守的措施已被用于愿意生育的患者。醋酸乌普利司是一种选择性孕酮受体调节剂，用于治疗平滑肌瘤引起的AUB。这是一篇关于使用乌普利司妥治疗子宫腺肌病的系统综述。从PubMed、SCOPUS和Cochrane图书馆检索到8篇符合条件的文章。迄今为止，仅发表了一项关于该问题的随机临床试验。醋酸乌普利司司似乎可以部分或完全缓解由子宫腺肌症引起的AUB，但有关其对盆腔疼痛的影响和该疾病的放射学表现的证据是相互矛盾的。然而，由于缺乏数据，对这个问题得出任何结论仍是初步的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecology and Minimally Invasive Therapy-GMIT OBSTETRICS & GYNECOLOGY-

CiteScore

2.00

自引率

16.70%

发文量

审稿时长

52 weeks